MedTrace has received a U.S. patent covering its PC MT-100 system for producing oxygen-15 (O-15), a myocardial perfusion imaging radiotracer.
The P3 MT-100 automated manufacturing system is currently in use at several hospitals around the world as part of a phase III clinical trial evaluating the diagnostic accuracy and safety of O-15 for visualizing myocardial blood flow. The system is designed to enable hospitals to produce O-15 tracer injections at the point of care without relying on third-party suppliers for radiopharmaceuticals, MedTrace said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
